Skip to content

Effectiveness of Online Mindfulness Platform in Improving Anxiety, Depression, and Stress in Adult

Effectiveness of Online Mindfulness Platform in Improving Anxiety, Depression, and Stress in Adults During the COVID-19 Pandemic: a Randomized Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06613529
Enrollment
60
Registered
2024-09-26
Start date
2022-11-09
Completion date
2023-03-08
Last updated
2024-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pandemic, Emotions, Online Mental Health Program

Keywords

COVID-19, physiology, psychology, Mindfulness, online mindfulness

Brief summary

During the COVID-19 pandemic, adults may experience emotional stress and impact. To reduce the risk of cross-infection, this study aims to use online mindfulness training to improve emotional well-being during the pandemic and assess their effectiveness.

Detailed description

he COVID-19 pandemic had a detrimental global impact on the health of most populations. It causes and also generates further damage to physiology and psychology. Mindfulness is recognized as an effective method for improving the symptoms of physical and mental problems. The purpose of this review will explore the efficacy of an online mindfulness intervention for individuals or groups that impacted symptoms of physiology and psychology in adults during the pandemic base on the principle of evidence-based medicine. At the same time, a set of mindfulness intervention plans will be developed based on the best evidence searched, and a pilot study will be conducted. Therefore, this research design will be divided into two stages. In the first stage, six electronic bibliographic databases will be comprehensively searched for randomized controlled trials that have been published from February 2020 to currently published articles. The research subjects are adults who live in the community and accept online mindfulness intervention. Quality assessment will be performed according to the Cochrane Collaboration's Risk of Bias tool will be used for randomized controlled clinical trials (RCTs). A meta-analysis of the intervention timing and measurements will be performed using Review Manager 5.1 software. The second phase will be a randomized controlled trial pilot study of mindfulness interventions, The research subjects will be divided into two groups, namely the mindfulness intervention experimental group (E) and the control group (C). The researcher uses structured questionnaires to collect data before intervention (To) and at 4 weeks (T1), 8 weeks (T2) after the intervention. Data will be analyzed using the Generalized Estimating Equation to analyze the repeated measurements and intention-to-treat analysis for reducing attrition bias.

Interventions

Use publicly available online mindfulness training resources. The training content was to guide patients to practice mindfulness techniques, including where the body is, the mind is and relaxation learning.

Sponsors

Taipei Medical University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 20 years of age * Conscious * Able to communicate in Taiwanese

Exclusion criteria

* Patients currently receiving antidepressant or anti-anxiety medications * Patients unable to communicate verbally * Patients who refuse to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Assessment of anxietyAnxiety was assessed before the intervention, and at 4 and 8 weeks after the intervention.Anxiety levels were assessed using the odd-numbered questions of the Hospital Anxiety and Depression Scale (HADS-14). The full title of HADS-14 is Hospital Anxiety and Depression Scale. This scale consists of 14 items, with 7 items specifically measuring anxiety, known as the Anxiety Subscale (HADS-A). Each item in the Anxiety Subscale is rated on a 4-point Likert scale, ranging from 0 (no symptoms) to 3 (significant symptoms). The total score for the anxiety subscale can range from 0 to 21. Higher scores indicate worse outcomes, specifically reflecting greater levels of anxiety. The scoring is categorized as follows: * 0-7: Normal anxiety levels * 8-10: Borderline abnormal anxiety (suggesting possible anxiety) * 11-21: Abnormal anxiety (indicating clinical levels of anxiety)

Secondary

MeasureTime frameDescription
Assessment of depressionDepression was assessed before the intervention, and at 4 and 8 weeks after the intervention.Depression levels were assessed using the even-numbered questions of the Hospital Anxiety and Depression Scale (HADS-14). This scale consists of 14 items, with 7 items specifically measuring depression, known as the The full title of HADS-14 is Hospital Anxiety and Depression Scale. Depression Subscale (HADS-D). Each item in the Depression Subscale is rated on a 4-point Likert scale, ranging from 0 (no symptoms) to 3 (significant symptoms). The total score for the depression subscale can range from 0 to 21. Higher scores indicate worse outcomes, specifically reflecting greater levels of depression. The scoring is categorized as follows: * 0-7: Normal depression levels * 8-10: Borderline abnormal depression (suggesting possible depression) * 11-21: Abnormal depression (indicating clinical levels of depression)

Other

MeasureTime frameDescription
Assessment of stressStress levels were assessed before the intervention, and at 4 and 8 weeks after the intervention.Stress levels were assessed using the Perceived Stress Scale (PSS-10). The full title of PSS-10 is Perceived Stress Scale. This scale consists of 10 items. Each item in the scale is rated on a 5-point Likert scale, ranging from 0 (Never) to 4 (Very Often). The total score ranges from 0 to 40. Higher scores indicate worse outcomes, specifically reflecting a higher perceived level of stress.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026